The phase 2 trial aimed to investigate the antitumor activity and safety of lorlatinib in TKI naïve in patients with advanced ROS1-positive NSCLC. The primary endpoint was to determine ORR. Researchers noticed lorlatinib’s effectiveness and safety, supporting earlier treatment for ROS1-positive NSCLC. ROS1 rearrangement is rare but an attractive therapeutic target in advanced […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Background: Some of the non–small cell lung cancer (NSCLC) cases enhance somatic mutations of the epidermal growth factor receptor (EGFR) gene within the tyrosine kinase inhibitor (TKI) domain. In such cases, first-line treatments are EGFR-TKIs, …
Objective: Multidisciplinary cancer consultations play a critical role in the delivery of quality cancer care by promoting treatment planning and collaborative decision-making. The objective of this study was to evaluate associations between multidisciplinary cancer consultations …
Objectives: Breast cancer, particularly the hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) subtype, remains a major global health concern. Abemaciclib, a CDK4/6 inhibitor, has shown promising results in treating advanced cases. …
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
